A recent study discovered that individuals using GLP-1 medications may develop severe acid reflux.Researchers discovered that ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

A similar study in Gastro Hep Advances found higher odds of GERD and gastroparesis among patients with type 2 diabetes taking GLP-1 agonists versus SGLT-2 inhibitors, but lower od ...

When patients were on a GLP-1 agonist for at least 1 year, they had a 30% lower risk for depression than DPP-4 inhibitor users (HR 0.70, 95% 0.59-0.82), and a trend towards a lower risk for ...

GLP-1 agonists and co-agonists conferred better respiratory and mortality outcomes among patients with COPD and type 2 diabetes. They also lowered recurrent risk for pneumonia, pulmonary edema and ...

Source Reference: Muayad J, et al "Comparative effects of GLP-1 receptor agonists and metformin on glaucoma risk in type 2 diabetes patients" Ophthalmology 2024; DOI: 10.1016/j.ophtha.2024.08.023.